The effects of astaxanthin supplementation on the expression of miR-146a
and miR-126, oxidative stress and inflammation in patients with type 2
diabetes mellitus: A randomized double blind placebo controlled clinical
trial
Abstract
Background: The pathogenesis of type 2 diabetes (T2D) is associated with
chronic oxidative stress and inflammation. It is well known that the
expression of some miRNAs such as miRNA-146a up- regulate in diabetic
and hyperglycemic patients whereas, circulating miRNA-126 reduces.
Therefore, the purpose of this study was to determinate the effects of
Astaxanthin supplementation on the expression of miR-146a and miR-126,
MDA and inflammation in patients with type 2 diabetes. Methods: This
randomized double-blind placebo-controlled clinical trial was conducted
on 44 type 2 diabetes patients who were randomly assigned to received
8mg of oral Astaxanthin/d (n=22) or placebo(n=22) for 8 weeks. Results:
We observed that Astaxanthin supplementation could decrease plasma
levels of MDA and IL-6 (P < 0.05) and declined the expression
level of miR-146a over time (Fold change: -1/388) (P < 0.05).
Conclusion: Astaxanthin supplementation might be beneficial for improving
circulating MDA and IL-6 and down regulation of miR-146a. However,
future investigations are suggested to confirm these results.
